| 陈伟伟 雷励 蔡少华 陈丽 党惠.康莱特注射液联合化疗治疗晚期非小细胞肺癌的临床疗效[J].,2015,15(20):3869-3871 |
| 康莱特注射液联合化疗治疗晚期非小细胞肺癌的临床疗效 |
| Clinical Efficacy of Kanglaite Injection Combined withChemotherapy in Treatment of Patients with AdvancedNon-small Cell lung Cancer |
| |
| DOI： |
| 中文关键词: 非小细胞肺癌 化疗 康莱特注射液 |
| 英文关键词: Non-small cell lung cancer Chemotherapy Kanglaite Injection |
| 基金项目:国家自然科学基金项目（30901795） |
|
| 摘要点击次数: 535 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨康莱特注射液联合化疗治疗晚期非小细胞肺癌患者的临床疗效。方法：选择我院60 例晚期非小细胞肺癌患者，
按随机数字表法平均分为两组各30 例，两组患者均给予NP化疗方案治疗，研究组患者在此基础上联合康莱特注射液治疗。比较
两组患者近期治疗疗效、生活质量Karnofsky评分、1 年生存率、中位生存时间、平均生存时间以及毒副反应发生情况。结果：研究
组患者近期治疗有效率为53.3%，明显高于对照组33.3%，比较差异具有统计学意义（X2=4.12，P<0.05）；研究组患者治疗后生活质
量Karnofsky 评分好转率为66.7%，明显高于对照组36.7%，比较差异具有统计学意义（X2=5.41，P<0.05）；研究组患者经治疗后1
年生存率、中位生存时间和平均生存时间分别为60.0%、15.0 个月和（11.0± 5.1）个月，均明显高于对照组30.0%、9.0 个月和（5.9±
4.8）个月，两组比较差异具有统计学意义（X2=5.45，t=5.24，6.12，P<0.05）；研究组患者治疗过程毒副反应恶心呕吐及白细胞下降发
生率均明显低于对照组，差异具有统计学意义（X2=4.27，5.08，P<0.05）。结论：康莱特注射液联合化疗治疗晚期非小细胞肺癌患者
的临床疗效显著，可明显改善患者生活质量，降低毒副反应发生率，值得临床推广应用。 |
| 英文摘要: |
| Objective:To investigate the clinical efficacy of Kanglaite Injection combined with chemotherapy in treatment of
patients with advanced non-small cell lung cancer.Methods:60 cases with advanced non-small cell lung cancer in our hospital were
randomly and equally divided into two groups. The two groups were all given NP chemotherapy regimen and the study group added
Kanglaite Injection. Then the short-term curative effect, Karnofsky scores of quality of life, one-year’s survival rate, median survival
time, average survival time and incidence of toxicity were compared between the two groups.Results:The short-termeffective rate of the
study group was 53.3% which was significantly higher than 33.3% of the control group with statistically significant difference(x2=4.12,
P<0.05); the improvement rate of Karnofsky score of quality of life in the study group was 66.7% which was significantly higher than
36.7% of the control group with statistically significant difference (x2=5.41, P<0.05); the one-year’s survival rate, median survival time
and the average survival time of the study group was 60%, 15 months and(11.0± 5.1) months, respectively, that were significantly higher
than 30%, 9.0 months and (5.9± 4.8) months of the control group, with statistically significant differences between the two groups(x2=5.
45, t=5.24, 6.12,P<0.05); the incidence of adverse reactions in the study group was significantly lower than that of the control group with
statistically significant difference between the two groups (x2=4.27, t=5.08, P<0.05).Conclusion:Kanglaite Injection combined with
chemotherapy has a significant clinical curative effect in treatment of patients with advanced non-small cell lung cancer, which can
significantly improve the life quality of patients, reduce the incidence of adverse reactions and is worthy of clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
